Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00027248|
Recruitment Status : Completed
First Posted : November 30, 2001
Last Update Posted : September 14, 2005
Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI).
BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI.
MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, may prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.
|Condition or disease||Intervention/treatment||Phase|
|Sepsis Bacteremia Fungemia||Drug: MBI 226||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1400 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization|
|Study Start Date :||September 2000|
|Study Completion Date :||July 2003|
- Reduction of catheter-related bloodstream infection
- Reduction of catheter colonization
- Reduction of local catheter site infection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00027248
|United States, Illinois|
|Omnicare Clinical Research Inc.|
|Lake Bluff, Illinois, United States, 60044|
|Study Director:||Jim Pankovich||BioWest Therapeutics Inc|